Rare bile duct cancer drug earns FDA approval

The FDA has approved Bizengri for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 gene fusion whose disease progressed on or after prior systemic therapy. Bizengri is the first approved treatment for patients with NRG1 fusion-positive cholangiocarcinoma, an ultra-rare cancer that forms in the bile ducts, according to a May 8 FDA […] The post Rare bile duct cancer drug earns FDA approval appeared first on Becker's Hospital Review | Healthcar...